Humacyte vs Korro Bio
Korro Bio is the larger business, with $6.4m of revenue in fiscal 2025 against $2.0m for Humacyte (3.1 times as much). Korro Bio kept more of each dollar of sales as profit: a net margin of -1834.5% against -2003.6%.
| Latest fiscal year | HumacyteHUMA, 2025 | Korro BioKRRO, 2025 |
|---|---|---|
| Revenue | $2.0m | $6.4m |
| Revenue growth | — | 181.5% |
| Net income | −$40.8m | −$117m |
| Operating margin | -5306.0% | — |
| Net margin | -2003.6% | -1834.5% |
| Return on equity | — | -110.7% |
| Free cash flow | −$106m | −$79.1m |
| Cash | $50.5m | $21.8m |
| Total debt | $35.4m | $0 |
| Debt to equity | 1140.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 184 | 58 |
| Market value | $120m | $235m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 5 buys, 2 sales | 16 buys, 33 sales |